Brief: Biophytis SA Looking To Licence-Out BI0101 To Regional Or Global Pharmaceutical Cos
29/04/2024 14:10
April 29 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS SA - LOOKING TO LICENCE-OUT BI0101
(20-HYDROXYECDYSONES) TO REGIONAL OR GLOBAL PHARMACEUTICAL
COMPANIES
* BIOPHYTIS SA - IMPLEMENTATION OF DEDICATED STRATEGY FOR
PARTNER
SEARCH IN OBESITY
* BIOPHYTIS SA: BIO101 IS IN CLINICAL DEVELOPMENT (PHASE 2
OBA
STUDY IN PREPARATION) IN OBESITY, IN COMBINATION WITH GLP-1
RECEPTOR AGONISTS (GLP1-RA)
Further company coverage: ALBPS.PA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon